Thelansis

  Malignant gliomas encompass various types, including glioblastomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, as well as rarer forms such as anaplastic ependymomas and anaplastic gangliogliomas. These tumors pose significant morbidity and mortality challenges. Glioblastomas typically yield a median survival of 12–15 months, even with optimal treatment, while anaplastic gliomas extend survival to 2–5 years. Recent strides in comprehending the molecular underpinnings of malignant gliomas have led to the emergence of targeted chemotherapeutic agents. Moreover, advancements in diagnostic imaging facilitate early detection and intervention. For certain patients with recurrent malignant glioma—specifically glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma—aggressive treatment can provide meaningful palliation. Surgical resection of recurrent lesions offers diagnostic and therapeutic benefits, mainly when ...

  Malignant gliomas consist of glioblastomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. With optimal treatment, the median survival for glioblastomas is only 12–15 months, and 2–5 years for anaplastic gliomas. Recent advances in our understanding of the molecular pathogenesis of malignant gliomas have resulted in the development of targeted chemotherapeutic agents. Furthermore, advances in diagnostic imaging have enabled the early detection and treatment of malignant gliomas. Meaningful palliation is possible for selected patients with recurrent malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma) using aggressive treatment. Although long-term disease-free survival occurs in fewer than 10% of patients, most who achieve such survival have been trea...